Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H25N6O8P |
Molecular Weight | 532.4431 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12O[C@@H](O[C@@]1([H])[C@@H](O[C@@H]2COP(O)(O)=O)N3C=NC4=C(NC(=O)NCC)N=CN=C34)\C=C\C5=CC=CC=C5
InChI
InChIKey=NXHAXEBZOXCDKD-XIXRRVGJSA-N
InChI=1S/C22H25N6O8P/c1-2-23-22(29)27-19-16-20(25-11-24-19)28(12-26-16)21-18-17(14(34-21)10-33-37(30,31)32)35-15(36-18)9-8-13-6-4-3-5-7-13/h3-9,11-12,14-15,17-18,21H,2,10H2,1H3,(H2,30,31,32)(H2,23,24,25,27,29)/b9-8+/t14-,15+,17-,18-,21-/m1/s1
Molecular Formula | C22H25N6O8P |
Molecular Weight | 532.4431 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Regrelor (INS50589) is a P2Y(12) ADP-receptor antagonist that regulates platelet function. Regrelor was found to be well-tolerated and have reversible effects. Its potential therapeutic utility in various cardiovascular settings has been studied. Initial results of canine models suggested that regrelor should be effective in protecting platelet function and reducing blood loss in human patients undergoing open-heart surgery. A phase II study testing regrelor for its safety and efficacy in reduction of postoperative bleeding and blood product transfusion was terminated due to adverse effects.
Originator
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:29:20 GMT 2023
by
admin
on
Fri Dec 15 15:29:20 GMT 2023
|
Record UNII |
Q6C8TY6SW1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1162175
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY | |||
|
11273179
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY | |||
|
Regrelor
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY | |||
|
DB05553
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY | |||
|
8830
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY | |||
|
Q6C8TY6SW1
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY | |||
|
DTXSID80229272
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY | |||
|
787548-03-2
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY | |||
|
1313722
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY | RxNorm | ||
|
C81575
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY | |||
|
300000036892
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY | |||
|
Q6C8TY6SW1
Created by
admin on Fri Dec 15 15:29:20 GMT 2023 , Edited by admin on Fri Dec 15 15:29:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|